Although Zenith hasn't been stellar in updating their website, it is good that in the upcoming conference call news release they continue to make this same statement that has appeared on their website for a while now, "Zenith's lead product is a pan selective BET inhibitor being developed for hematological malignancies and solid tumors. Zenith is targeting the second half of 2015 to file an IND for hematological malignancies and solid tumors." This statement has been consistent ever since they terminated their plan for clinical trial of ZEN003365 (https://clinicaltrials.gov/ct2/show/NCT02238522?term=zenith&rank=46)

So it's looking like H2 2015 will have good news for both Zenith and Resverlogix, though I'm not exactly sure what IND-filing means in the grand scheme of planning/executing a clinical trial.